Suppr超能文献

个体化血管医学:个体化药物治疗。

Personalized vascular medicine: individualizing drug therapy.

机构信息

Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, USA.

出版信息

Vasc Med. 2011 Oct;16(5):391-404. doi: 10.1177/1358863X11422251.

Abstract

Personalized medicine refers to the application of an individual's biological fingerprint - the comprehensive dataset of unique biological information - to optimize medical care. While the principle itself is straightforward, its implementation remains challenging. Advances in pharmacogenomics as well as functional assays of vascular biology now permit improved characterization of an individual's response to medical therapy for vascular disease. This review describes novel strategies designed to permit tailoring of four major pharmacotherapeutic drug classes within vascular medicine: antiplatelet therapy, antihypertensive therapy, lipid-lowering therapy, and antithrombotic therapy. Translation to routine clinical practice awaits the results of ongoing randomized clinical trials comparing personalized approaches with standard of care management.

摘要

个性化医疗是指应用个体的生物指纹 - 即独特的生物信息综合数据集 - 来优化医疗护理。虽然这一原则本身很简单,但实施起来仍然具有挑战性。药物基因组学的进步以及血管生物学的功能检测现在使得对个体对血管疾病的医疗治疗的反应进行更好地描述成为可能。这篇综述描述了旨在允许对血管医学中的四大类主要药物治疗类别进行定制的新策略:抗血小板治疗、降压治疗、降脂治疗和抗血栓治疗。将其转化为常规临床实践需要等待正在进行的比较个性化方法与标准护理管理的随机临床试验的结果。

相似文献

1
Personalized vascular medicine: individualizing drug therapy.
Vasc Med. 2011 Oct;16(5):391-404. doi: 10.1177/1358863X11422251.
2
Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.
Curr Mol Med. 2014;14(7):849-79. doi: 10.2174/1566524014666140811115517.
3
The next 10 years in personalized medicine in cardiology.
Expert Rev Cardiovasc Ther. 2013 Aug;11(8):933-5. doi: 10.1586/14779072.2013.814823.
4
Novel treatments for cardiovascular disease prevention.
Cardiovasc Ther. 2012 Oct;30(5):257-63. doi: 10.1111/j.1755-5922.2011.00280.x. Epub 2011 May 31.
5
The Role of Pharmacogenetics in Antithrombotic Therapy Management: New Achievements and Barriers Yet to Overcome.
Curr Med Chem. 2021;28(32):6675-6703. doi: 10.2174/0929867328666201231124715.
6
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur Heart J. 2009 Aug;30(16):1943-63. doi: 10.1093/eurheartj/ehp295. Epub 2009 Jul 28.
7
The pharmacogenetics of antiplatelet agents: towards personalized therapy?
Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111.
8
Comprehensive medical management of peripheral arterial disease.
Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):2-13. doi: 10.1016/j.pcad.2011.02.004.
9
Medical and lifestyle management of peripheral arterial disease.
J Vasc Surg. 2018 Nov;68(5):1595-1606. doi: 10.1016/j.jvs.2018.07.027.
10
Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.
PLoS One. 2019 Jan 18;14(1):e0210988. doi: 10.1371/journal.pone.0210988. eCollection 2019.

引用本文的文献

2
Quantile-dependent expressivity of postprandial lipemia.
PLoS One. 2020 Feb 26;15(2):e0229495. doi: 10.1371/journal.pone.0229495. eCollection 2020.
4
Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.
Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12.
5
Personalized medicine in cardiovascular diseases.
Korean Circ J. 2012 Sep;42(9):583-91. doi: 10.4070/kcj.2012.42.9.583. Epub 2012 Sep 27.
6
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.
Semin Nephrol. 2012 Sep;32(5):407-14. doi: 10.1016/j.semnephrol.2012.07.002.

本文引用的文献

2
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.
Pharmacogenomics J. 2012 Oct;12(5):417-24. doi: 10.1038/tpj.2011.18. Epub 2011 May 24.
5
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.
8
The relationship of vitamin D deficiency to statin myopathy.
Atherosclerosis. 2011 Mar;215(1):23-9. doi: 10.1016/j.atherosclerosis.2010.11.039. Epub 2010 Dec 5.
9
Paraoxonase-1 is a major determinant of clopidogrel efficacy.
Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19.
10
Aspirin resistance: Fact or fiction? A point of view.
World J Cardiol. 2010 Sep 26;2(9):280-8. doi: 10.4330/wjc.v2.i9.280.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验